Guselkumab Improves Symptoms and Disease Progression in Psoriatic Arthritis
Treatment with guselkumab led to improved joint symptoms and reduced radiographic progression compared to placebo in biologic-naïve adults with active psoriatic arthritis.
Guselkumab, a selective interleukin (IL)-23p19 inhibitor, significantly improves joint symptoms and prevents radiographic disease progression with a favorable safety profile consistent with prior trials.
- The APEX trial is an ongoing, multicenter, randomized, double-blind, placebo-controlled phase 3b study.
- Researchers enrolled biologic-naïve adults with active psoriatic arthritis (≥3 tender and swollen joints, C-reactive protein ≥0.
Guselkumab significantly improves joint symptoms and prevents radiographic disease progression.
Author's summary: Guselkumab improves symptoms in psoriatic arthritis.
More News
- Lawrence O'Donnell Rips Republicans for Vacationing More During Shutdown Than 'Most Americans Get in 3 Years' | Video
- US Determined to Prevent the Collapse of the Gaza Ceasefire After Overnight Airstrikes
- 'Selling Sunset' Star Chrishell Stause Calls Her Parents 'Bad *sses' After Fiery Confrontation With Nicole Young
- Narco-Terrorist Take Down by US Gutting Caribbean Gang-Crime
- Jimmy Butler issues “scary” warning to the rest of the NBA amid Warriors’ 4-1 start
- Canada’s LNG industry is less regulated than you might think
- Luke Bryan Shares the God Moment That 'Set Me Free' After His Sister's Death
- Luke Bryan's Family Guide: All About His Parents, Sister and Brother
- Selling Sunset's Mary Bonnet Thinks Producers Set Up Chelsea Conflict
- Xbox Network and Minecraft Go Down After Major Microsoft Azure Outage | iPhone in Canada